|
Bravo-Perez C, Fernandez-Caballero M, Soler-Espejo E, Garcia-Torralba E, Sorigue M, Garcia-Malo MD, Jerez A, Vicente V, Roldan V, de Arriba F. Heparin versus aspirin thromboprophylaxis adds independent value to IMPEDE-VTE score for venous thrombosis prediction in multiple myeloma. J Thromb Thrombolysis. 2021 Oct;52(3):848-853. doi: 10.1007/s11239-021-02407-5. Epub 2021 Mar 1. PubMed PMID: 33649980.
AÑO: 2021; IF: 5.221
|
33649980
|
Solano de la Asuncion C, Terol MJ, Saus A, Olea B, Gimenez E, Albert E, Lopez-Jimenez J, Andreu R, Garcia D, Fox L, Remigia MJ, Amat P, Solano C, Navarro D. Cytomegalovirus-specific T-cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib. Br J Haematol. 2021 Nov;195(4):637-641. doi: 10.1111/bjh.17732. Epub 2021 Aug 16. No abstract available. PubMed PMID: 34402042.
AÑO: 2021; IF: 5.1
|
|
Bravo-Perez C, Pajares I, Muina B, Escobar H, Amigo ML, Garcia-Malo MD, Garcia J, Rodriguez-Pinilla SM, Piris MA, Ortuno FJ. Double hit B cell precursor leukemia/lymphoma in a patient with a prior diagnosis of follicular lymphoma: a diagnostic and therapeutic dilemma. Ann Hematol. 2020 Feb;99(2):391-393. doi: 10.1007/s00277-019-03897-3. Epub 2019 Dec 20. No abstract available. PubMed PMID: 31858188.
AÑO: 2020; IF: 3.673
|
|
Fernandez-Caballero M, Salmeron D, Dolores Chirlaque M, Chen-Liang TH, Hurtado AM, Garcia Malo MD, Ortuno FJ, Roldan V, Vicente V, Jerez A, De Arriba F. Increasing therapy-related myeloid neoplasms in multiple myeloma. Eur J Clin Invest. 2019 Feb;49(2):e13050. doi: 10.1111/eci.13050. Epub 2018 Dec 7. PubMed PMID: 30422316.
AÑO: 2019; IF: 3.481
|
|
Garcia-Marco JA, Jimenez JL, Recasens V, Zarzoso MF, Gonzalez-Barca E, De Marcos NS, Ramirez MJ, Parraga FJP, Yanez L, De La Serna Torroba J, Malo MDG, Ariznavarreta GD, Persona EP, Guinaldo MAR, De Paz Arias R, Llanos EB, Jarque I, Valle MDCF, Tatay AC, De Oteyza JP, Martin EMD, Fernandez IP, Martinez RM, Costa MAA, Champ D, Suarez JG, Diaz MG, Ferrer S, Carbonell F, Garcia-Vela JA; GELLC Study Group. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance. Haematologica. 2019 Nov;104(11):2249-2257. doi: 10.3324/haematol.2018.204891. Epub 2019 Mar 19. PubMed PMID: 30890600; PubMed Central PMCID: PMC6821631.
AÑO: 2019; IF: 7.116
|